Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowThis study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard immunosuppressive drugs for generalized myasthenia gravis. About 66 adults who have not responded to at least two prior therapies will be randomly assigned to receive either …
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
CAR T-Cell therapy: what happens years later?
Knowledge-focused Recruiting nowThis study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC